3rd Department of Cardiology, Silesian Centre for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland.
Department of Cardiology and Cardiovascular Interventions, University Hospital, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
Kardiol Pol. 2024;82(2):166-174. doi: 10.33963/v.phj.98889.
Notwithstanding readily available revascularization, significant advancements in mechanical circulatory support, and pharmacological progress, cardiogenic shock (CS) secondary to unprotected left main culprit lesion-related acute myocardial infarction (ULMCL-related AMI) is associated with very high mortality. In this population, chronic total occlusion (CTO) is relatively frequent.
This study sought to assess the association between the presence of CTO and 12-month mortality in patients with CS due to ULMCL-related AMI.
The study included consecutive patients admitted for AMI-related CS with ULMCL who underwent percutaneous coronary intervention (PCI) and were enrolled in the prospective Polish Registry of Acute Coronary Syndromes (PL-ACS) between January 2017 and December 2021. The patients were stratified into two groups based on the presence of at least one CTO. The primary endpoint was all-cause death at 12 months. Of the 250 included patients, 60 (24%) patients had one or more CTOs of a major coronary artery (+CTO), and in 190 (76%) patients, the presence of CTO was not observed (-CTO). The 12-month mortality rates for the +CTO and -CTO patients were 85% and 69.8%, respectively (P log-rank = 0.03). After multivariable adjustment for differences in the baseline characteristics, the presence of CTO remained significantly associated with higher 12-month mortality (hazard ratio, 1.423; 95% CI, 1.027-1.973; P = 0.034).
Our analysis showed that in patients with CS due to ULMCL-related AMI treated with PCI, the presence of CTO is associated with worse 12-month prognosis.
尽管有可获得的血运重建、机械循环支持的显著进展和药理学的进步,但与无保护左主干罪犯病变相关的急性心肌梗死(ULMCL 相关 AMI)相关的心源性休克(CS)仍然与极高的死亡率相关。在这一人群中,慢性完全闭塞(CTO)相对较为常见。
本研究旨在评估与 ULMCL 相关 AMI 所致 CS 患者中 CTO 的存在与 12 个月死亡率之间的关系。
该研究纳入了 2017 年 1 月至 2021 年 12 月期间因 ULMCL 相关 AMI 接受经皮冠状动脉介入治疗(PCI)并被纳入前瞻性波兰急性冠状动脉综合征注册研究(PL-ACS)的连续患者。根据是否存在至少一支 CTO,将患者分为两组。主要终点为 12 个月时的全因死亡。在 250 名纳入的患者中,60 名(24%)患者存在一支或多支主要冠状动脉 CTO(+CTO),而在 190 名(76%)患者中未观察到 CTO 的存在(-CTO)。+CTO 和 -CTO 患者的 12 个月死亡率分别为 85%和 69.8%(P log-rank = 0.03)。在对基线特征差异进行多变量调整后,CTO 的存在仍与较高的 12 个月死亡率显著相关(危险比,1.423;95%置信区间,1.027-1.973;P = 0.034)。
我们的分析表明,在接受 PCI 治疗的 ULMCL 相关 AMI 所致 CS 患者中,CTO 的存在与 12 个月预后较差相关。